Bass, Berry & Sims attorney Jeff Davis provided comment for a recent Fierce Healthcare article that examined newly released Health Resources & Services Administration (HRSA) data showing that outpatient drug purchases through the 340B Drug Pricing Program exceeded $100 billion in 2025, representing a 23% increase over 2024. HRSA attributed the increase in part to shifts in care from inpatient to outpatient settings, growth in specialty drug utilization, and rising use of therapies in areas such as oncology and immunology.
“HRSA flagged that certain therapeutic areas are key drivers of national growth, and these same therapeutic areas are reflected in the top drugs accounting for a disproportionate share of 340B spending, such as oncology,” Jeff told Fierce Healthcare. He added that “HRSA’s data highlight that looking at 340B spending figures alone without considering this broader context does not paint a full picture of how the 340B program is evolving.”
The article also highlights the ongoing policy debate surrounding the 340B program, including pharmaceutical manufacturer challenges, proposed reimbursement changes, and congressional reform efforts as stakeholders continue to examine the program’s growth and role in supporting safety-net providers.
The full article, “340B drug purchases hit at least $100B in 2025, administrator reports,” was published by Fierce Healthcare on July 15 and is available online.